← SynDRA
LY-3200882
SynDRA canonical compound SYN0040058 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | TGFBR1 |
|---|
| Mechanism of action | TGF beta receptor inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- TGF beta receptor inhibitor
- TGFBR1 INHIBITOR
Cross-references
Synonyms
- LY3200882
- PNPFMWIDAKQFPY-UHFFFAOYSA-N
- 2-{4-[(4-{[1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl]oxy}pyridin-2-yl)amino]pyridin-2-yl}propan-2-ol
- 2-(4-((4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)oxy)pyridin-2-yl)amino)pyridin-2-yl)propan-2-ol
- SCHEMBL17645407
- EX-A1680
- BCP20882
- HY-103021
- CS-0023129
- UNII-19HY34R6UN
- RefChem:154553
- TGFb Inhibitor LY 3200882
- TGFBETA INHIBITOR LY3200882
- LY 3200882 [WHO-DD]
- orb1302068
- SCHEMBL30290837
- GLXC-15294
- BDBM50564620
- MFCD31619238
- NSC802451
- s8772
- AKOS037515641
- AT10669
- NSC-802451
- NCGC00537540-01
- AC-31400
- BS-15855
- SY251060
- LY3200882?
- T5125
- L960010
Look up LY-3200882 in the interactive SynDRA portal →